Impossible Foods, which makes plant-based nuggets, burgers and patties, is reportedly laying off 20% of its staff, Bloomberg reported first. TechCrunch reports: According to the story, the 12-year-old company currently employs about 700 workers, which could then affect over 100 employees. This comes as the company made a 6% reduction in its workforce last October. While we know layoffs can happen anytime, it seems like the company was doing well. Earlier this month, the Redwood City, California-based company reported a year of record sales that included over 50% dollar sales growth in 2022. The company also touted that its Impossible Beef product was "the best-selling product by volume of any plant-based meat brand in the U.S." Months before that, CEO Peter McGuinness said in an interview with Bloomberg Technology that the company had a strong balance sheet, good cash flow and growth of between 65% to 70%. In total, Impossible raised $1.9 billion in venture capital, according to Crunchbase data. The last time the company raised capital was a $500 million Series H round in November 2021, and it was at that time that the company was valued at $7 billion. [...] Impossible is not the only plant-based meat alternative company to make layoffs in recent months. In a regulatory filing made last October, Beyond Meat said it planned to lay off about 200 employees, or 19% of its workforce, as part of cost-saving measures as sales were slumping.

Read more of this story at Slashdot.

The New York Times looks at the AbbVie's anti-inflammatory drug Humira and their "savvy but legal exploitation of the U.S. patent system." Though AbbVie's patent was supposed to expire in 2016, since then it's maintained a monopoly that generated $114 billion in revenue by using "a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year." AbbVie did not invent these patent-prolonging strategies; companies like Bristol Myers Squibb and AstraZeneca have deployed similar tactics to maximize profits on drugs for the treatment of cancer, anxiety and heartburn. But AbbVie's success with Humira stands out even in an industry adept at manipulating the U.S. intellectual-property regime.... AbbVie and its affiliates have applied for 311 patents, of which 165 have been granted, related to Humira, according to the Initiative for Medicines, Access and Knowledge, which tracks drug patents. A vast majority were filed after Humira was on the market. Some of Humira's patents covered innovations that benefited patients, like a formulation of the drug that reduced the pain from injections. But many of them simply elaborated on previous patents. For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a type of arthritis that causes inflammation in the joints, among other diseases. In 2014, AbbVie applied for another patent for a method of treating ankylosing spondylitis with a specific dosing of 40 milligrams of Humira. The application was approved, adding 11 years of patent protection beyond 2016. AbbVie has been aggressive about suing rivals that have tried to introduce biosimilar versions of Humira. In 2016, with Amgen's copycat product on the verge of winning regulatory approval, AbbVie sued Amgen, alleging that it was violating 10 of its patents. Amgen argued that most of AbbVie's patents were invalid, but the two sides reached a settlement in which Amgen agreed not to begin selling its drug until 2023. Over the next five years, AbbVie reached similar settlements with nine other manufacturers seeking to launch their own versions of Humira. All of them agreed to delay their market entry until 2023. A drug pricing expert at Washington University in St. Louis tells the New York Times that AbbVie and its strategy with Humira "showed other companies what it was possible to do." But the article concludes that last year such tactics "became a rallying cry" for U.S. lawmakers "as they successfully pushed for Medicare to have greater control over the price of widely used drugs that, like Humira, have been on the market for many years but still lack competition."

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: Eight years ago, a patient lost her power of speech because of ALS, or Lou Gehrig's disease, which causes progressive paralysis. She can still make sounds, but her words have become unintelligible, leaving her reliant on a writing board or iPad to communicate. Now, after volunteering to receive a brain implant, the woman has been able to rapidly communicate phrases like "I don't own my home" and "It's just tough" at a rate approaching normal speech. That is the claim in a paper published over the weekend on the website bioRxiv by a team at Stanford University. The study has not been formally reviewed by other researchers. The scientists say their volunteer, identified only as "subject T12," smashed previous records by using the brain-reading implant to communicate at a rate of 62 words a minute, three times the previous best. [...] People without speech deficits typically talk at a rate of about 160 words a minute. Even in an era of keyboards, thumb-typing, emojis, and internet abbreviations, speech remains the fastest form of human-to-human communication. The brain-computer interfaces that [co-lead author Krishna Sehnoy's] team works with involve a small pad of sharp electrodes embedded in a person's motor cortex, the brain region most involved in movement. This allows researchers to record activity from a few dozen neurons at once and find patterns that reflect what motions someone is thinking of, even if the person is paralyzed. In previous work, paralyzed volunteers have been asked to imagine making hand movements. By "decoding" their neural signals in real time, implants have let them steer a cursor around a screen, pick out letters on a virtual keyboard, play video games, or even control a robotic arm. In the new research, the Stanford team wanted to know if neurons in the motor cortex contained useful information about speech movements, too. That is, could they detect how "subject T12" was trying to move her mouth, tongue, and vocal cords as she attempted to talk? These are small, subtle movements, and according to Sabes, one big discovery is that just a few neurons contained enough information to let a computer program predict, with good accuracy, what words the patient was trying to say. That information was conveyed by Shenoy's team to a computer screen, where the patient's words appeared as they were spoken by the computer. [...] The current system already uses a couple of types of machine learning programs. To improve its accuracy, the Stanford team employed software that predicts what word typically comes next in a sentence. "I" is more often followed by "am" than "ham," even though these words sound similar and could produce similar patterns in someone's brain. Adding the word prediction system increased how quickly the subject could speak without mistakes.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the BBC: It was landing at Singapore's international airport a decade ago that sparked Shara Ticku's idea to create a lab-grown alternative to palm oil. "In 2013 I flew to Singapore, and when I landed I had to wear a mask," says the boss of US tech firm C16 Biosciences. "The air was toxic because they were burning the rainforest in Indonesia." Indonesian farmers, who were clearing land for palm oil and other crops, were blamed for the fires and the smoke that drifted across the sea to Singapore. Fast forward to today, and her business has just commercially released an alternative to palm oil that is created from yeast cells. Palm oil remains the world's most-produced vegetable oil, accounting for 40% of the total, according to the World Wide Fund for Nature (WWF). [...] The widely-documented problem with this usage is that this demand for palm oil has led to significant deforestation in areas where oil palm trees can grow -- low-lying, hot, wet areas near the equator. The use of this land for palm oil cultivation, 85% of which is in Indonesia and Malaysia, has increased almost nine-fold from 3.3 million hectares (eight million acres) in 1970 to 28.7 million hectares in 2020. In financial terms, one report valued the worldwide palm oil industry at $62.3 billion in 2021. And such is the continuing growth in demand, this figure is expected to increase to $75.7 billion by 2028. To try to reduce the world's reliance on palm oil, Ms Ticku, who was formerly an investment banker, and her co-founders set up C16 Biosciences in New York City in 2018. Backed by multi-million dollar funding from Microsoft founder Bill Gates, the company has spent the past four years developing and finessing their product, which is called Palmless. They grow a strain of yeast that naturally produces an oil with very similar properties to palm, which they harvest. The yeast is fed on sugars from sugar cane plants grown on land already used for arable farming. "Our process takes less than seven days from start to finish," says a spokeswoman for C16 Biosciences. "For a traditional oil palm tree, the oil wouldn't be ready to harvest until years after the seed is planted, and most trees don't reach peak production until seven years later." She adds that the company is now "actively collaborating on partnerships in the beauty and home categories -- for example, moisturizers, nourishing oils, soaps and cancels". "[And] we plan to enter into food in 2024." Chris Chuck, professor of bioprocess engineering at the University of Bath, leads another team that has created its own yeast-sourced alternative. "After hundreds of generations of yeast, and years of trial and error, they arrived at a unique strain called metschnikowia pulcherrima, or MP for short," reports the BBC. "MP is said to be hardy and not fussy what it eats. It can be fed on grass and food waste. And at the point of harvesting, its cells are full of oil. Even the leftover yeast cell biomass need not go to waste. It can be used for other products, for example creating a substitute for soya protein." Prof Chuck says the aim is for the oil to be as sustainable as possible. "In the best case scenarios we've modeled," he says, "it could be even just a couple of percent of the greenhouse gas emissions from palm oil grown in Indonesia or Malaysia."

Read more of this story at Slashdot.

"In Boston labs, old, blind mice have regained their eyesight, developed smarter, younger brains and built healthier muscle and kidney tissue," reports CNN: On the flip side, young mice have prematurely aged, with devastating results to nearly every tissue in their bodies. The experiments show aging is a reversible process, capable of being driven "forwards and backwards at will," said anti-aging expert David Sinclair, a professor of genetics in the Blavatnik Institute at Harvard Medical School and codirector of the Paul F. Glenn Center for Biology of Aging Research. Our bodies hold a backup copy of our youth that can be triggered to regenerate, said Sinclair, the senior author of a new paper showcasing the work of his lab and international scientists. The combined experiments, published for the first time Thursday in the journal Cell, challenge the scientific belief aging is the result of genetic mutations that undermine our DNA, creating a junkyard of damaged cellular tissue that can lead to deterioration, disease and death. "It's not junk, it's not damage that causes us to get old," said Sinclair, who described the work last year at Life Itself, a health and wellness event presented in partnership with CNN. "We believe it's a loss of information — a loss in the cell's ability to read its original DNA so it forgets how to function — in much the same way an old computer may develop corrupted software. I call it the information theory of aging." Jae-Hyun Yang, a genetics research fellow in the Sinclair Lab who coauthored the paper, said he expects the findings "will transform the way we view the process of aging and the way we approach the treatment of diseases associated with aging." While Sinclair is now testing "genetic resets" in primates, the article warns that "decades could pass before any anti-aging clinical trials in humans begin, get analyzed and, if safe and successful, scaled to the mass needed for federal approval." But Sinclair suggests damage could probably also be repaired through healthy behaviors like exercise and sufficient sleep, social support and lower stress levels, eating less often and focusing on plants. Thanks to long-time Slashdot reader 192_kbps for sharing the story.

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: A small biotech company claims it has used a technology called reprogramming to rejuvenate old mice and extend their lives, a result suggesting that one day older people could have their biological clocks turned back with an injection -- literally becoming younger. The life-extension claim in rodents, made by Rejuvenate Bio, a San Diego biotech company, appears in a preprint paper on the website BioRxiv and hasn't been peer reviewed. Noah Davidsohn, chief scientific officer of Rejuvenate, says the company used gene therapy to add three powerful reprogramming genes to the bodies of mice that were equivalent in age to human 77-year-olds. After the treatment, their remaining life span was doubled, the company says. Treated mice lived another 18 weeks, on average, while control mice died in nine weeks. Overall, the treated mice lived about 7% longer. Although the increase in lifespan was modest, the company says the research provides a demonstration of age reversal in an animal. "This is a powerful technology, and here is the proof of concept," says Davidsohn. "I wanted to show that it's actually something we can do in our elderly population." Scientists not connected to the company called the study an exciting landmark but cautioned that whole-body rejuvenation using gene therapy remains a poorly understood concept with huge risks. "It's a beautiful intellectual exercise, but I would shy away from doing anything remotely similar to a person," says Vittorio Sebastiano, a professor at Stanford University. One risk is that the powerful programming process can cause cancer. Such an effect is often seen in mice. Even so, the chance that reprogramming could be an elixir of youth has led to a research and investment boom. One company, Altos Labs, says it has raised over $3 billion. "Far more information will be needed to learn exactly what changes the reprogramming genes cause in the mice, and researchers say other groups will need to repeat the experiment before they are convinced," adds the report. "Sebastiano says the life-extension effect reported by Rejuvenate could be due to changes in a single organ or group of cells, rather than a general mouse-wide rejuvenation effect. Among other shortfalls in its research, Rejuvenate did not carefully document which and how many cells were changed by the genetic treatment."

Read more of this story at Slashdot.

"Wheat now provides 20% of the calories consumed by humans every day," writes the Guardian. Unfortunately, "Thanks to human-induced global heating, our planet faces a future of increasingly severe heat waves, droughts and wildfires that could devastate harvests in future, triggering widespread famine in their wake. "But the crisis could be averted thanks to remarkable research now being undertaken by researchers at the John Innes Centre in Norwich." They are working on a project to make wheat more resistant to heat and drought. Such efforts have proved to be extremely tricky but are set to be the subject of a new set of trials in a few weeks as part of a project in which varieties of wheat — created, in part, by gene-editing technology — will be planted in field trials in Spain. The ability of these varieties to withstand the heat of Iberia will determine how well crop scientists will be able to protect future arable farms from the worst vicissitudes of climate change, and so bolster food production for the Earth's billions, says the John Innes Centre team.... "A key tool in this work was gene editing, which allowed us to make precise changes in wheat DNA. Without it, we would still be struggling with this. It has made all the difference." This was an especially difficult struggle because wheat genetics includes multiple ancestral genomes, the article points. Thanks to long-time Slashdot reader schwit1 for submitting the story.

Read more of this story at Slashdot.

An anonymous reader quotes a report from CNBC: Former Theranos chief operating officer and president Ramesh "Sunny" Balwani was sentenced to nearly 13 years in prison Wednesday for fraud, after the unraveling of the blood-testing juggernaut prompted criminal charges in California federal court against both Balwani and Theranos founder Elizabeth Holmes, who on Nov. 18 was sentenced to more than 11 years in prison. During the sentencing hearing, attorneys for Balwani attempted to pin the blame on Holmes, telling U.S. District Court Judge Edward J. Davila that "decisions were made by Elizabeth Holmes." Davila had set a sentencing range of 11 years plus 3 months to 14 years, but prosecutors today sought a 15-year sentence given his "significant" oversight role at Theranos' lab business. The final guideline sentence was 155 months, plus three years of probation. Davila set a Mar. 15, 2023, surrender date. [...] Balwani's sentencing in federal court marks the end of the Theranos saga, which enthralled the public and prompted documentary films and novel treatments.

Read more of this story at Slashdot.

For the first time, America's Food and Drug Administration has "approved a treatment that can delay the onset of Type 1 diabetes," reports ABC News: Teplizumab, a monoclonal antibody that will be marketed under the brand name Tzield from pharmaceutical companies ProventionBio and Sanofi, is administered through intravenous infusion. The injection was shown in clinical trials to delay onset of insulin-dependent Type 1 diabetes for patients with autoantibody markers of early risk by over two years, with hopes for some that it can delay onset even longer.... Tzield was approved to delay the onset of stage 3 Type 1 diabetes in adults and children ages 8 and up who currently have stage 2 Type 1 diabetes. The medication is thought to slow down the body's attack on its own insulin-producing cells and thus give people more time before they become dependent on pharmaceutical insulin. Tzield is not suitable for people with insulin-dependent Type 1 diabetes, people who are pre-Type 2 diabetics or those with type 2 diabetes. "This approval is a watershed moment for the treatment and prevention of type 1 diabetes," said Dr. Mark S. Anderson, director of the University of California San Francisco Diabetes Center. "Until now, the only real therapy for patients has been a lifetime of insulin replacement. This new therapy targets and helps to halt the autoimmune process that leads to the loss of insulin...." Studies have shown that 75% of people with these diagnostic markers usually become insulin-dependent within five years and nearly 100% at some point in their lifetime. ABC News also shares this quote from Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research. "The drug's potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease."

Read more of this story at Slashdot.

Theranos founder Elizabeth Holmes was sentenced Friday in a federal court to 135 months, more than 11 years in prison following her conviction on four counts of criminal fraud. The court found she deceived investors, including News Corp.'s Rupert Murdoch and a host of other luminaries, about the efficacy of Theranos' blood-testing technology. CNBC reports: Holmes cried while speaking to the court ahead of her sentencing. "I loved Theranos. It was my life's work," Holmes said. "My team meant the world to me. I am devastated by my failings. I'm so so sorry. I gave everything I had to build my company." Her defense team argued she should face a maximum sentence of 18 months, according to court filings. The Wall Street Journal first broke the story of how Theranos' blood-testing technology was struggling to meet expectations in 2015. Whistleblowers and other witnesses came forth to provide detailed accounts of how Holmes and former operating chief Ramesh "Sunny" Balwani deceived patients, partners, investors and employees about the company's progress and the capabilities of its technology. "Thank you for having me. Thank you for the courtesy and respect you have shown me," she said Friday. "I have felt deep pain for what people went through because I failed them. To investors, patients, I am sorry." Prosecutors sought a 15 year sentence for the pregnant 38-year-old former billionaire and Silicon Valley celebrity. Developing...

Read more of this story at Slashdot.

An anonymous reader quotes a report from Motherboard: The Queensland, Australia police have used DNA phenotyping for the first time ever in hopes of leading to a breakthrough for a 1982 murder. The department partnered with a U.S.-based company called Parabon NanoLabs to create a profile image of the murder suspect, a Caucasian man with long blonde hair. Police claim that this image was generated using blood samples found at the scene of the murder of a man from 40 years ago; according to the Australian Broadcasting Corporation this is the first time "investigative genetic genealogy" has been used in Queensland. This image does not factor in any environmental characteristics, such as tattoos, facial hair, and scars, and cannot determine the age or body mass of the suspect. However, Queensland investigators have published the image online and are offering a $500,000 reward and indemnity from prosecution to anyone who might have information about the suspect. The image is a vague rendering of a man that does not provide any more information than the sketch that the department already has of the suspect. This further perpetuates the hyper-surveillance of any man who resembles the image. Parabon NanoLabs has already been criticized by criminal justice and privacy experts for disseminating images that implicate too broad a pool of suspects. The Queensland police department said that the DNA sample from the case generated a genealogy tree of "15,000 'linked' individuals" and they have not been able to find a close match yet. Instead of facing the possibility that DNA phenotyping may not be an effective tool for narrowing down a suspect, the police department's strategy is to ask the public for their DNA samples. Criminologist Xanthe Mallett said in a press release that to help police find a match, people can "opt-in" to share their own DNA samples with investigators through DNA services such as Family Tree and GEDMatch. "Many members of the public that see this generated image will be unaware that it's a digital approximation, that age, weight, hairstyle, and face shape may be very different, and that accuracy of skin/hair/eye color is approximate," said Callie Schroeder, the Global Privacy Counsel at the Electronic Privacy Information Center.

Read more of this story at Slashdot.

Long-time Slashdot reader mspohr shares a report from the Boston Globe's health-news site STAT: The scientist flicked on a laser, filling the rat's brain with blue light. The rodent, true to its past two weeks of training, scampered across its glass box to a tiny spout, where it was duly rewarded with a drink of water. From the outside, this would appear to be a pretty run-of-the-mill neuroscience experiment, except for the fact that the neurons directing the rat to its thirst-quenching reward didn't contain any rat DNA. Instead, they came from a human "mini-brain" — a ball of human tissue called an organoid — that researchers at Stanford University School of Medicine had grown in a lab and implanted in the rodent's cortex months before. The experiment — part of a study published Wednesday in Nature — is the first describing human neurons influencing another species' behavior. The study also showed that signals could go the other way; tendrils of human neurons mingled with the rodent brain cells and fired in response to air rustling the rats' whiskers. The advance opens the door to using such human-rodent chimeras to better understand how the human brain develops and what goes wrong in neurological and psychiatric conditions such as schizophrenia, autism, and epilepsy. When the Stanford scientists implanted organoids grown from the cells of patients with a severe genetic brain disorder, they could watch the neurons develop abnormally with unprecedented clarity. "This paper really pushes the envelope," said neuroscientist Tomasz Nowakowski, of the University of California, San Francisco, who uses brain organoids in his research on neurodevelopmental disorders but was not involved in the new work. "The field is desperate for more experimental models. And what's really important about this study is it demonstrates that brain organoids can complete their maturation trajectory when transplanted. So it really expands our toolkit for asking more nuanced questions about how genetic mutations lead to behavioral disorders." It's an example of how stem cells have revolutionized brain research. By "doing their experiments in very young rats whose cortexes are not yet saturated with synapses," the article points out, the researchers "found that the human neurons easily integrated into the animals' rapidly expanding circuitry, which provided them with the stimulation they needed to push past previous developmental barriers."

Read more of this story at Slashdot.

Emily Mullin writes via Wired: The human genome is made of more than 6 billion letters, and each person has a unique configuration of As, Cs, Gs, and Ts -- the molecular building blocks that make up DNA. Determining the sequence of all those letters used to take vast amounts of money, time, and effort. The Human Genome Project took 13 years and thousands of researchers. The final cost: $2.7 billion. That 1990 project kicked off the age of genomics, helping scientists unravel genetic drivers of cancer and many inherited diseases while spurring the development of at-home DNA tests, among other advances. Next, researchers started sequencing more genomes: from animals, plants, bacteria, and viruses. Ten years ago, it cost about $10,000 for researchers to sequence a human genome. A few years ago, that fell to $1,000. Today, it's about $600. Now, sequencing is about to get even cheaper. At an industry event in San Diego today, genomics behemoth Illumina unveiled what it calls its fastest, most cost-efficient sequencing machines yet, the NovaSeq X series. The company, which controls around 80 percent of the DNA sequencing market globally, believes its new technology will slash the cost to just $200 per human genome while providing a readout at twice the speed. Francis deSouza, Illumina's CEO, says the more powerful model will be able to sequence 20,000 genomes per year; its current machines can do about 7,500. Illumina will start selling the new machines today and ship them next year. Illumina's sequencers use a method called "sequencing by synthesis" to decipher DNA. This process first requires that DNA strands, which are usually in double-helix form, be split into single strands. The DNA is then broken into short fragments that are spread onto a flow cell -- a glass surface about the size of a smartphone. When a flow cell is loaded into the sequencer, the machine attaches color-coded fluorescent tags to each base: A, C, G, and T. For instance, blue might correspond to the letter A. Each of the DNA fragments gets copied one base at a time, and a matching strand of DNA is gradually made, or synthesized. A laser scans the bases one by one while a camera records the color coding for each letter. The process is repeated until every fragment is sequenced. For its latest machines, Illumina invented denser flow cells to increase data yield and new chemical reagents, which enable faster reads of bases. "The molecules in that sequencing chemistry are much stronger. They can resist heat, they can resist water, and because they're so much tougher, we can subject them to more laser power and can scan them faster. That's the heart of the engine that allows us to get so much more data faster and at lower costs," says Alex Aravanis, Illumina's chief technology officer. Illumina's new system comes at a steep cost of around $1 million, which makes them more difficult for smaller labs and hospitals to acquire. They also often require experts to run the machines and process the data. That said, "Illumina's sequencers are completely automated and produce a report comparing each sample against a reference genome," reports Wired. "Aravanis says this automation could democratize sequencing, so that facilities without large teams of scientists and engineers can run the machines with few resources."

Read more of this story at Slashdot.

Citing McDonald's shelved meat-free burger trial and a 70% dip in Beyond Meat's stock, The Guardian suggests plant-based meats may not interest Americans as much as investors thought. From the report: Getting meat eaters in the US to adopt plant-based alternatives has proven a challenge. Beyond Meat, which produces a variety of plant-based products, including imitations of ground beef, burgers, sausages, meatballs and jerky, has had a rough 12 months, with its stock dipping nearly 70%. Multiple chains that partnered with the company, including McDonald's, have quietly ended trial launches. In August, the company laid off 4% of its workforce after a slowdown in sales growth. Last week, its chief operating officer was reportedly arrested for biting another man on the nose during a road rage confrontation. It's a dramatic reversal of fortune. Just two years ago, Beyond Meat, its competitor Impossible Foods and the plant-based meat industry at large seemed poised to start a food revolution. For a time, Wall Street went vegetarian. In 2019 Beyond Meat was valued at over $10 billion, more than Macy's or Xerox. The most bullish investors believed that plant-based meat would make up 15% of all meat sales by 2030. But the reality of Americans' interest in plant-based meat has proven more complicated than investors thought, and the adoption of meat alternatives has been slower than what was once hoped. Today Beyond Meat is valued at just over $900 million. The sobering story is similar to those experienced by many new ventures that see exhilarating hype after a flood of Silicon Valley venture capital cash, fueled by excitement about innovation. Bill Gates backed Beyond Meat, and a number of venture capital firms that typically invest in tech startups funneled money to startups making plant-based meat. Even the meat industry's biggest players have, ironically, invested in companies coming up with plant-based meat. While eating plant-based meat (or no meat at all) has been shown to be the most effective thing individual consumers can do to fight climate change, "consumers seem hesitant to adapt their behavior when the environment -- not their health or wallets -- is the sole beneficiary," reports The Guardian. "Despite the increasing alarm over climate change, the number of Americans who are vegetarian or vegan has remained relatively stable over the last 20 years." "Even when participants in a study conducted at Purdue University in Indiana were given information about the carbon footprint of meat production, participants were more likely to go with regular meat over a plant-based alternative."

Read more of this story at Slashdot.

Intellia Therapeutics reported encouraging early-stage study results for its Crispr gene-editing treatments, the latest sign that the pathbreaking technology could result in commercially available drugs in the coming years. The Wall Street Journal reports: Intellia said Friday that one of its treatments, code-named NTLA-2002, significantly reduced levels of a protein that causes periodic attacks of swelling in six patients with a rare genetic disease called hereditary angioedema, or HAE. In a separate study building on previously released trial data, Intellia's treatment NTLA-2001 reduced a disease-causing protein by more than 90% in 12 people with transthyretin-mediated amyloidosis cardiomyopathy, or ATTR-CM, a genetic disease that can lead to heart failure. Despite the positive results, questions remain about whether therapies based on Crispr will work safely and effectively, analysts said. Intellia's latest studies involved a small number of patients, and were disclosed in news releases and haven't been published in a peer-reviewed journal. The NTLA-2002 study results were presented at the Bradykinin Symposium in Berlin, a medical meeting focused on angioedema. The data came from small, so-called Phase 1 studies conducted in New Zealand and the U.K. that didn't include control groups. Results from such early studies can be unreliable predictors of a drug's safety and effectiveness once the compound is tested in larger numbers of patients. The findings, nevertheless, add to preliminary but promising evidence of the potential for drugs based on the gene-editing technology. Last year, Intellia said that NTLA-2001 reduced the disease-causing protein involved in ATTR patients.

Read more of this story at Slashdot.

Bruce66423 shares a report from the Associated Press: A rape victim whose DNA from her sexual assault case was used by San Francisco police to arrest her in an unrelated property crime on Monday filed a lawsuit against the city. During a search of a San Francisco Police Department crime lab database, the woman's DNA was tied to a burglary in late 2021. Her DNA had been collected and stored in the system as part of a 2016 domestic violence and sexual assault case, then-District Attorney Chesa Boudin said in February in a shocking revelation that raised privacy concerns. "This is government overreach of the highest order, using the most unique and personal thing we have -- our genetic code -- without our knowledge to try and connect us to crime," the woman's attorney, Adante Pointer, said in a statement. The revelation prompted a national outcry from advocates, law enforcement, legal experts and lawmakers. Advocates said the practice could affect victims' willingness to come forward to law enforcement authorities. Federal law already prohibits the inclusion of victims' DNA in the national Combined DNA Index System. There is no corresponding law in California to prohibit local law enforcement databases from retaining victims' profiles and searching them years later for entirely different purposes. Boudin said the report was found among hundreds of pages of evidence against a woman who had been recently charged with a felony property crime. After learning the source of the DNA evidence, Boudin dropped the felony property crime charges against the woman. The police department's crime lab stopped the practice shortly after receiving a complaint from the district attorney's office and formally changed its operating procedure to prevent the misuse of DNA collected from sexual assault victims, Police Chief Bill Scott said. Scott said at a police commission meeting in March that he had discovered 17 crime victim profiles, 11 of them from rape kits, that were matched as potential suspects using a crime victims database during unrelated investigations. Scott said he believes the only person arrested was the woman who filed the lawsuit Monday.

Read more of this story at Slashdot.

A federal judge on Thursday tentatively declined to overturn the jury conviction of disgraced Theranos CEO Elizabeth Holmes on four felony counts of fraud and conspiracy. That leaves the former Silicon Valley star a step closer to serving prison time. Politico reports: U.S. District Judge Edward Davila won't make that decision final until Oct. 17, when he is scheduled to sentence Holmes in the same San Jose, California, courtroom where a jury found her guilty of duping investors in her much-hyped blood-testing startup. Holmes, 38, faces up to 20 years in prison and a $250,000 fine, plus restitution, for lying to investors about a Theranos technology she hailed as a revolution in healthcare but which in practice produced dangerously inaccurate results.

Read more of this story at Slashdot.

Live and high-resolution images of a patient's internal organs are already possible with ultrasound imaging technology. But currently the technology "requires bulky and specialized equipment available only in hospitals and doctor's offices," explains an annoncement from MIT. Now a new design by MIT engineers "might make the technology as wearable and accessible as buying Band-Aids at the pharmacy." In a paper appearing today in Science, the engineers present the design for a new ultrasound sticker — a stamp-sized device that sticks to skin and can provide continuous ultrasound imaging of internal organs for 48 hours. The researchers applied the stickers to volunteers and showed the devices produced live, high-resolution images of major blood vessels and deeper organs such as the heart, lungs, and stomach. The stickers maintained a strong adhesion and captured changes in underlying organs as volunteers performed various activities, including sitting, standing, jogging, and biking.... From the stickers' images, the team was able to observe the changing diameter of major blood vessels when seated versus standing. The stickers also captured details of deeper organs, such as how the heart changes shape as it exerts during exercise. The researchers were also able to watch the stomach distend, then shrink back as volunteers drank then later passed juice out of their system. And as some volunteers lifted weights, the team could detect bright patterns in underlying muscles, signaling temporary microdamage. "With imaging, we might be able to capture the moment in a workout before overuse, and stop before muscles become sore," says Chen. "We do not know when that moment might be yet, but now we can provide imaging data that experts can interpret." They're already envisioning other possibilities: If the devices can be made to operate wirelessly — a goal the team is currently working toward — the ultrasound stickers could be made into wearable imaging products that patients could take home from a doctor's office or even buy at a pharmacy. "We envision a few patches adhered to different locations on the body, and the patches would communicate with your cellphone, where AI algorithms would analyze the images on demand," says the study's senior author, Xuanhe Zhao, professor of mechanical engineering and civil and environmental engineering at MIT. "We believe we've opened a new era of wearable imaging: With a few patches on your body, you could see your internal organs."

Read more of this story at Slashdot.

"In what's being hailed as an important first for chemistry, an international team of scientists has developed a new technology that can selectively rearrange atomic bonds within a single molecule," reports New Atlas. "The breakthrough allows for an unprecedented level of control over chemical bonds within these structures, and could open up some exciting possibilities in what's known as molecular machinery." "Selective chemistry — the ability to steer reactions at will and to form exactly the chemical bonds you want and no others — is a long-standing quest in chemistry," adds the announcement from IBM Research. "Our team has been able to achieve this level of selectivity in tip-induced redox reactions using scanning probe microscopy." Our technique consisted in using the tip of a scanning probe microscope to apply voltage pulses to single molecules. We were able to target specific chemical bonds in those molecules, breaking those bonds and forging new, different ones to switch back and forth at will among three different molecular structures. The molecules in our experiment all consisted of the same atoms, but differed in the way those atoms were bonded together and arranged in space... Our findings were published today and featured on the cover of Science. Our demonstration of selective and reversible formation of intramolecular covalent bonds is unprecedented. It advances our understanding of chemical reactions and opens a route towards advanced artificial molecular machines.... Imagine one could rearrange bonds inside a molecule at will, transforming one structural isomer into various other ones in a controlled manner. In this paper, we describe a system and a method to make exactly that possible — including the control of the direction of the atomic rearrangements by means of an external driving voltage, and without the use of reagents. Thanks to Slashdot reader Grokew for sharing the story!

Read more of this story at Slashdot.

Serhat Gumrukcu faces trial in a purported plot to kill an associate who could have exposed him and derailed a drug-development deal worth millions. From a report: Even as a teenager back in Turkey, Serhat Gumrukcu dazzled audiences. In a 2002 video, he opened one of his magic shows dancing with a cane that appeared to be levitating. He was introduced as a medical student and went by the stage name "Dr. No." A little more than a decade later, not long after Mr. Gumrukcu arrived in the U.S., he had his hand in multimillion-dollar oil and real-estate deals. Yet his best-known venture was in medicine. For a time, he thrilled investors with ideas for groundbreaking treatments and drew special notice from the government's top infectious-disease official, Anthony Fauci. In America, the magician had found a new, more lucrative audience. Enochian Biosciences co-founded by Mr. Gumrukcu in 2018, paid more than $21 million to companies controlled by Mr. Gumrukcu and his husband for consulting, research and the licensing of potential drugs to treat influenza, hepatitis B, HIV and Covid-19, company financial filings show. "Dr. Gumrukcu is one of those rare geniuses that is not bound by scientific discipline or dogma. He sees connections and opportunities often missed," Enochian Vice Chairman Mark Dybul, now chief executive, said in a 2019 news release about Enochian's licensing of a hepatitis B drug from a company controlled by Mr. Gumrukcu. Mr. Gumrukcu's success as a biotech entrepreneur afforded the purchase last year of an $18.4 million office complex in North Hollywood, a neighborhood in Los Angeles, and, earlier, a $5.5 million house in the Hollywood Hills. Yet much of what people saw in Mr. Gumrukcu was an illusion he cast, misrepresenting himself and his credentials, according to state and federal authorities, court records, former colleagues and those who have sued and won judgments against him over fraudulent medical and financial dealings. Prosecutors now allege that Mr. Gumrukcu arranged the murder of a business associate, Gregory Davis, who threatened to expose him as a fraud. Such a revelation would have put at risk the 39-year-old entrepreneur's deal with Enochian, they said. Mr. Gumrukcu has been in custody at the Metropolitan Detention Center in Los Angeles since his arrest on May 24. A federal grand jury indicted him on murder conspiracy charges, an offense punishable by death.

Read more of this story at Slashdot.